N.E.W. Advisory Services LLC Has $1.60 Million Position in Johnson & Johnson (NYSE:JNJ)

N.E.W. Advisory Services LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 8.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,772 shares of the company’s stock after acquiring an additional 736 shares during the quarter. N.E.W. Advisory Services LLC’s holdings in Johnson & Johnson were worth $1,604,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Family CFO Inc bought a new stake in Johnson & Johnson in the 4th quarter valued at $26,000. Steward Financial Group LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at $34,000. Advocacy Wealth Management Services LLC boosted its stake in Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after purchasing an additional 67 shares during the period. Iron Horse Wealth Management LLC boosted its stake in Johnson & Johnson by 29.9% in the 4th quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock valued at $45,000 after purchasing an additional 61 shares during the period. Finally, Gibson Wealth Advisors LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at $49,000. 68.78% of the stock is currently owned by institutional investors and hedge funds.

In other news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The disclosure for this sale can be found here. In the last ninety days, insiders sold 78,161 shares of company stock valued at $13,895,302. Insiders own 0.35% of the company’s stock.

Shares of JNJ opened at $179.66 on Friday. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The business has a 50-day simple moving average of $177.65 and a two-hundred day simple moving average of $173.20. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. The stock has a market cap of $472.76 billion, a PE ratio of 24.21, a PEG ratio of 3.42 and a beta of 0.66.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its earnings results on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.60 by $0.07. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The business had revenue of $23.43 billion during the quarter, compared to analysts’ expectations of $23.62 billion. During the same quarter in the prior year, the firm earned $2.59 EPS. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. On average, equities research analysts expect that Johnson & Johnson will post 10.23 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date of this dividend was Monday, May 23rd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s dividend payout ratio is presently 60.92%.

JNJ has been the subject of a number of recent analyst reports. Citigroup cut their target price on Johnson & Johnson from $210.00 to $205.00 in a research report on Tuesday, May 17th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Daiwa Capital Markets initiated coverage on Johnson & Johnson in a research report on Wednesday. They set an “outperform” rating for the company. Morgan Stanley cut their target price on Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 6th. Finally, Credit Suisse Group boosted their price target on Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $190.50.

About Johnson & Johnson (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.